Showing results (301-310 of 313) with videos related to
Sort By:
Pageof 32
General Hospital Psychiatry|February 22, 2023
The COVID-19 pandemic's impact on all-cause mortality disparities in Medicare: By race, income, chronic health, mental/behavioral health, disabilityKaryn Kai Anderson, Sha Maresh, Andrew Ward, et al.Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|September 11, 2014
Elevated vascular level of ortho-tyrosine contributes to the impairment of insulin-induced arterial relaxationI A Szijártó, G A Molnár, E Mikolás, et al.Cancer|May 13, 2008
Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicityAmar Safdar, Gilhen H Rodriguez, Adriana M Rueda, et al.Cancer|February 28, 2007
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemiaAhmed Aribi, Hagop M Kantarjian, Elihu H Estey, et al.European Journal of Applied Physiology|April 25, 2000
Effects of hypobaric hypoxia on vascular endothelial growth factor and the acute phase response in subjects who are susceptible to high-altitude pulmonary oedemaV Pavlicek, H H Marti, S Grad, et al.Blood|August 1, 2002
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemiaAlessandra Ferrajoli, Michael J Keating, Taghi Manshouri, et al.Cancer|December 12, 2003
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemiaSusan M O'Brien, Hagop M Kantarjian, Deborah A Thomas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemiaM Beran, E Estey, S O'Brien, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemiasFrancis J Giles, Stefan Faderl, Deborah A Thomas, et al.Cell Stem Cell|October 30, 2012
Regulation of pluripotency and cellular reprogramming by the ubiquitin-proteasome systemShannon M Buckley, Beatriz Aranda-Orgilles, Alexandros Strikoudis, et al.Pageof 32